The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: Plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies

British Journal of Radiology

Volumn 85, Issue 1012, 2012, Pages 423-432

  Hussein, Mohammad ^a   Aldridge, S ^a   Guerrero Urbano, T ^a   Nisbet, A ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; METASTASIS; NEUTRON RADIATION; OUTCOME ASSESSMENT; PROBABILITY; PROSTATE CANCER; RADIATION DOSE; RECTUM; RISK ASSESSMENT; TREATMENT PLANNING; VOXEL BASED MORPHOMETRY;

HUMANS; MALE; MODELS, THEORETICAL; NEOPLASMS, RADIATION-INDUCED; PHANTOMS, IMAGING; PROBABILITY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS; THERMOLUMINESCENT DOSIMETRY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84859154803     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/24514638     Document Type: Article

References (51)

1. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Rad Oncol Biol Phys 2001;51:880-914.
2. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of secondary cancers. Int J Rad Oncol Biol Phys 2006;65:1-7.
3. d'Errico F. Dosimetric issues in radiation protection of radiotherapy patients. Rad Prot Dosim 2006;118:205-12.
4. Parzall A, Carol MP, Pickett B, Xia P, Roach M, Verhey LJ. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Rad Oncol Biol Phys 2002;53:434-42. (Pubitemid 34522109)
5. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004;59:267-84. (Pubitemid 38501532)
6. Ruben JD, Davis S, Evans C, Jones P, Gagliardi F, Haynes M, et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 2008;70:1530-6.
7. Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys 1997;38:667-72. (Pubitemid 27305029)
8. Hall EJ, Wuu C-S. Radiation-induced second cancers: the impact of 3D CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8. (Pubitemid 36403679)
9. Stathakis S, Li J, Ma CCM. Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity-modulated radiation therapy. J Applied Clin Med Phys 2007;8:14-27.
10. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Rad Oncol Biol Phys 2005;62:1195-203. (Pubitemid 40884435)
11. NCRP Report 116. Limitation of exposure to ionizing radiation. Bethesda, MD: National Council on Radiation Protection and Measurements, 1993.
12. Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol 2007;52:973-82.
13. Schneider U, Lomax A, Lombriser N. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation. Radiat Res 2000;154:382-8.
14. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumours. Int J Radiat Oncol Biol Phys 2002;54:824-9.
15. Upton AC. Radiobiological effects of low doses. Implications for radiological protection. Radiat Res 1977;71:51-74.
16. Daşu A, Toma-Daşu I, Olofsson J, Karlsson M. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncologica 2005;44:829-35.
17. UNSCEAR. Sources and effects of ionizing radiation 1993. Report to the General Assembly, with annexes. New York, NY: United Nations, 1993.
18. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer - the CHHiP trial. Clin Oncol 2008;20:12-14.
19. Sanchez-Nieto B, Nahum AE. BIOPLAN: software for the biological evaluation of radiotherapy treatment plan. Med Dosim 2000;25:71-6. (Pubitemid 30336646)
20. Webb S, Nahum AE. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distribution of dose and clonogenic cell density. Phys Med Biol 1993;38:653-66. (Pubitemid 23188329)
21. Sanchez-Nieto B, Nahum AE. The delta-TCP concept: a clinically useful measure of tumour control probability. Int J Radiat Oncol Biol Phys 1999;44:369-80. (Pubitemid 29205036)
22. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101. (Pubitemid 29144800)
23. Zelefsky MJ, Chan H, Hunt M, Yamanda Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-19. (Pubitemid 44307191)
24. Levegrün S, Jackson A, Zelefsky MJ, Skwarchuck MW, Venkatraman ES, Schlegel W, et al. Fitting tumour control probability models to biopsy outcome after three-dimensional conformal radiation therapy for prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. Int J Rad Oncol Biol Phys 2001;51:1064-80. (Pubitemid 33026439)
25. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res 1985;8:S13-S19. (Pubitemid 16149302)
26. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys 1999;26:1100.
27. Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 1991;21:137-46.
28. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-35.
29. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76:S123-9.
30. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010;76:S116-22.
31. Fiorini CF, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects of normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009;93:153-67.
32. Emami B, Lyman J, BrownA, Coia L,Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Rad Oncol Biol Phys 1991;21:109-22.
33. Alderson SW. Radio-therapy phantom. Patent number: 3 310 885. New York, 1967.
34. ICRP 103. The 2007 Recommendations of the International Commission on Radiological Protection. Oxford, UK: ICRP, 2007.
35. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol 1961;5:255-8.
36. NCRP Report 151. Structural shielding design and evaluation for megavoltage X-ray and gamma-ray radiotherapy facilities. Bethesda, MD: National Council on Radiation Protection and Measurements, 2005.
37. Bartlett DT, Greenhalgh JR. Calculations of effective dose equivalent, ambient dose equivalent and individual dose equivalent for a set of reference neutron spectra and field geometries. Health Physics 1986;50:548-50. (Pubitemid 16166347)
38. Thomas DJ, Bardell AG, Macaulay EM. Characterisation of a gold foil-based Bonner sphere set and measurements of neutron spectra at a medical accelerator. Nuc Instr and Meth A 2002;476:31-5. http://144.206.159.178/ft/787/47073/840015. pdf. (Pubitemid 33149565)
39. Howell RM, Hertel NE, Wang Z, Hutchinson J, Fullerton GD. Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies. Med Phys 2006;33:360-8. (Pubitemid 43183978)
40. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Rad Oncol Biol Phys 2005;62:1204-16. (Pubitemid 40884436)
41. Muirhead CR, Cox R, Stather JW, MacGibbon BH, Edwards AA, Haylock RG. Estimates of late radiation risks to the UK population. Didcot, UK: NRPB, 1993.
42. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radioth Oncol 1999;53:199-203.
43. Ruben JD, Lancaster CM, Jones P, Smith RL. A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis. Int J Rad Oncol Biol Phys 2011;81:1458-64.
44. Dorr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Strahlenther. Onkol 2002;178:357-62.
45. Reft CS, Runkel-Muller R, Myrianthopoulos L. In vivo and photon measurements of secondary photon and neutron doses for prostate patients undergoing 18 MV IMRT. Med Phys 2006;33:3734-42.
46. Becker J, Brunckhorst E, Schmidt R. Investigation of the neutron contamination in IMRT deliveries with a paired magnesium and boron coated magnesium ionization chamber system. Radiother Oncol 2008;86:182-6.
47. Kry SF, Salehpour M, Titt U, White RA, Stovall M, Followill DS. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy. Radiother Oncol 2009;91: 132-7.
48. Sachs RK, Brenner DJ. Solid tumour risks after high doses of ionizing radiation. PNAS 2005;102:13040-5. (Pubitemid 41324975)
49. Shuryak I, Sachs RK, Hlatky L, Little MP, Hahnfeldt P, Brenner DJ. Radiation-induced leukemia at doses relevant to radiation therapy: modelling mechanisms and estimating risk. J Natl Cancer Inst 2006;98:1794-1806. (Pubitemid 46017931)
50. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1265-71. (Pubitemid 47048597)
51. Aoyama H, Westerly DC, Mackie TM, Olivera GH, Bentzen SM, Patel RR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Rad Oncol Biol Phys 2006;64:962-7. (Pubitemid 43183600)